Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD raised its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 10,982.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,268,509 shares of the company’s stock after acquiring an additional 1,257,063 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Kodiak Sciences were worth $12,622,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in KOD. Silverarc Capital Management LLC raised its holdings in Kodiak Sciences by 100.0% in the 4th quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $9,950,000 after acquiring an additional 500,000 shares during the last quarter. Invesco Ltd. increased its stake in Kodiak Sciences by 545.7% in the fourth quarter. Invesco Ltd. now owns 519,010 shares of the company’s stock valued at $5,164,000 after purchasing an additional 438,635 shares during the last quarter. Peapod Lane Capital LLC purchased a new position in Kodiak Sciences during the fourth quarter worth about $1,660,000. JPMorgan Chase & Co. boosted its stake in Kodiak Sciences by 194.9% in the 4th quarter. JPMorgan Chase & Co. now owns 131,646 shares of the company’s stock worth $1,310,000 after buying an additional 86,998 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Kodiak Sciences in the 4th quarter valued at about $405,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating and set a $3.00 price objective on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Trading Up 6.9 %

Shares of Kodiak Sciences stock opened at $4.80 on Friday. The business’s fifty day moving average price is $3.27 and its 200 day moving average price is $5.46. Kodiak Sciences Inc. has a twelve month low of $1.92 and a twelve month high of $11.60. The stock has a market capitalization of $253.21 million, a P/E ratio of -1.32 and a beta of 2.40.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.06. As a group, sell-side analysts predict that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.